UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Nature reviews. Cancer, 2019-09, Vol.19 (9), p.495-509

2019

Volltextzugriff (PDF)

Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Clinical cancer research, 2017-02, Vol.23 (3), p.618-622

2017

Volltextzugriff (PDF)

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature (London), 2021-09, Vol.597 (7878), p.732-737

2021

Volltextzugriff (PDF)

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Clinical cancer research, 2016-02, Vol.22 (3), p.609-620

2016

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Volltextzugriff (PDF)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001001

2020

Volltextzugriff (PDF)

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

Clinical cancer research, 2016-12, Vol.22 (23), p.5851-5863

2016

Volltextzugriff (PDF)

Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes

Clinical cancer research, 2021-02, Vol.27 (4), p.913-915

Skoulidis, Ferdinandos

2021

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors

The American journal of gastroenterology, 2023-09, Vol.118 (9), p.1609-1617

2023

Volltextzugriff (PDF)

Bone morphogenetic protein 7 promotes resistance to immunotherapy

Nature communications, 2020-09, Vol.11 (1), p.4840-14, Article 4840

2020

Volltextzugriff (PDF)

Abstract SY42-02: Inactivating STK11/LKB1 genomic alterations are a major driver of primary resistance to PD-1 axis blockade in non-squamous non-small cell lung cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.SY42-02-SY42-02

Skoulidis, Ferdinandos

2019

Volltextzugriff (PDF)

De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer

The FASEB journal, 2018-06, Vol.32 (12), p.7018-7027

2018

Volltextzugriff (PDF)

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy

Nature communications, 2020-10, Vol.11 (1), p.5144-5144, Article 5144

2020

Volltextzugriff (PDF)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

BMC cancer, 2020-01, Vol.20 (1), p.83-11, Article 83

2020

Volltextzugriff (PDF)

SY6-1. Dissecting and targeting KRAS-mutated non-small cell lung cancer

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.500-500

Ferdinandos Skoulidis

2022

Volltextzugriff (PDF)

Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor

Molecular cancer therapeutics, 2011-04, Vol.10 (4), p.670-678

2011

Volltextzugriff (PDF)

926 Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A971-A971

2021

Volltextzugriff (PDF)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

JTO clinical and research reports, 2023-08, Vol.4 (8), p.100533-100533, Article 100533

2023

Volltextzugriff (PDF)

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100623, Article 100623

2024

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(110)

Publikationsform

Sprache

Englisch
(126)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(51)
Humans
(44)
Oncology
(40)
Lung Neoplasms - Drug Therapy
(30)
Mutation
(25)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(22)
Immunotherapy
(20)
Lung Cancer
(19)
Lung Neoplasms - Genetics
(19)
Female
(15)
Respiratory System
(15)
Middle Aged
(14)
Carcinoma, Non-Small-Cell Lung - Genetics
(13)
Chemotherapy
(13)
Male
(13)
Adult
(12)
Animals
(12)
Tumors
(12)
Cancer Therapies
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes

Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors

Bone morphogenetic protein 7 promotes resistance to immunotherapy

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer

Abstract SY42-02: Inactivating STK11/LKB1 genomic alterations are a major driver of primary resistance to PD-1 axis blockade in non-squamous non-small cell lung cancer

De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer

Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

SY6-1. Dissecting and targeting KRAS-mutated non-small cell lung cancer

Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor

926 Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets

Suchergebnisse filtern